| Literature DB >> 24069445 |
Lisa Seifert1, Michaela Harbeck, Astrid Thomas, Nadja Hoke, Lothar Zöller, Ingrid Wiechmann, Gisela Grupe, Holger C Scholz, Julia M Riehm.
Abstract
Yersinia pestis has been identified as the causative agent of the Black Death pandemic in the 14(th) century. However, retrospective diagnostics in human skeletons after more than 600 years are critical. We describe a strategy following a modern diagnostic algorithm and working under strict ancient DNA regime for the identification of medieval human plague victims. An initial screening and DNA quantification assay detected the Y. pestis specific pla gene of the high copy number plasmid pPCP1. Results were confirmed by conventional PCR and sequence analysis targeting both Y. pestis specific virulence plasmids pPCP1 and pMT1. All assays were meticulously validated according to human clinical diagnostics requirements (ISO 15189) regarding efficiency, sensitivity, specificity, and limit of detection (LOD). Assay specificity was 100% tested on 41 clinically relevant bacteria and 29 Y. pseudotuberculosis strains as well as for DNA of 22 Y. pestis strains and 30 previously confirmed clinical human plague samples. The optimized LOD was down to 4 gene copies. 29 individuals from three different multiple inhumations were initially assessed as possible victims of the Black Death pandemic. 7 samples (24%) were positive in the pPCP1 specific screening assay. Confirmation through second target pMT1 specific PCR was successful for 4 of the positive individuals (14%). A maximum of 700 and 560 copies per µl aDNA were quantified in two of the samples. Those were positive in all assays including all repetitions, and are candidates for future continuative investigations such as whole genome sequencing. We discuss that all precautions taken here for the work with aDNA are sufficient to prevent external sample contamination and fulfill the criteria of authenticity. With regard to retrospective diagnostics of a human pathogen and the uniqueness of ancient material we strongly recommend using a careful strategy and validated assays as presented in our study.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24069445 PMCID: PMC3775804 DOI: 10.1371/journal.pone.0075742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The investigated ancient samples originated from three different burial sites.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Manching-Pichl, Germany | 1250-1500 | 20 (4) | |||||
| MP17-I | 4/4 | 560 | 3/3 | 2/3 | |||
| MP19-II | 4/4 | 700 | 3/3 | 1/2 | |||
| MP59-I | 4/4 | 22 | 3/3 | 1/3 | |||
| MPS01-I | 4/4 | 3 | 1/3 | 0/2 | |||
| Brandenburg, Germany | 1640 | 3 (3) | |||||
| B1 | 1/4 | ≤ 1 | 0/3 | n.d. | |||
| B2 | 2/4 | 2 | 0/3 | n.d. | |||
| B3 | 4/4 | 6 | 2/3 | 1/2 | |||
| Basel, Switzerland | 1300-1490 | 6 (0) | neg | ||||
|
| 0/4 | 0/3 | n.d. |
Overall results are summarized in Table S1.
PCR assay results are generated from the first DNA extraction round, following the most efficient method [33].
Figure 1Schematic workflow for the proceeding through highly optimized and validated protocols for the detection of from ancient samples.
Origin of DNA used as specificity panel, positive and negative samples.
|
|
|
|
|
|
|---|---|---|---|---|
|
| Pestoides | G8786 Georgia | + | + |
|
| Antiqua 1.ANT | Margaret | + | + |
|
| Antiqua 1.ANT | CEB87-021 (343) | + | + |
|
| Antiqua 1.ANT | NCTC_570 Bombay267 | + | + |
|
| Antiqua 1.ANT | NCTC_10029 13925/58 | + | + |
|
| Antiqua 2.ANT | Kuma | + | + |
|
| Antiqua 2.ANT | Yokohama | + | + |
|
| Antiqua | Kenya 129 | + | + |
|
| Medievalis | KIM | + | + |
|
| Medievalis | Pestis Kurdistan Rodent 24 | + | + |
|
| Medievalis | Pestis Kurdistan Rodent 28 | + | + |
|
| Orientalis | EV76, vaccine strain | + | + |
|
| Orientalis | NCTC_2028 | + | + |
|
| Orientalis | NCTC_8775 139L | + | + |
|
| Orientalis | CEB02-417, Vietnam | + | + |
|
| Orientalis | Java10 | + | + |
|
| Orientalis | K120-43 87/30 | + | + |
|
| Orientalis | CEB02-107 (6/69) | + | + |
|
| Orientalis | Bara Banki 3 | + | + |
|
| Orientalis | CEB02-455 | + | + |
|
| Orientalis | M23 | + | + |
|
| Orientalis | TS | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M401 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M402 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M403 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M404 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M406 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M407 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M408 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M409 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M410 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M411 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M412 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M413 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M414 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M415 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M418 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M421 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M422 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M423 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M424 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M425 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M426 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M427 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M429 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M431 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M432 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M433 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M435 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M437 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M438 | + | + |
|
| Orientalis | Confirmed clinical sample, Madagascar, M439 | + | + |
|
| DSM 7324 | - | - | |
|
| Vollum | - | - | |
|
| ATCC 10987 | - | - | |
|
| DSM 7264 | - | - | |
|
| DSM 2046 | - | - | |
|
| ATCC 23456 | - | - | |
|
| NCTC 10744 | - | - | |
|
| ATCC_23344 | - | - | |
|
| ATCC_23343 | - | - | |
|
| DSM 13276 | - | - | |
|
| ATCC 29482 | - | - | |
|
| ATCC 36232 | - | - | |
|
| ATCC 53592 | - | - | |
|
| DSM 30039 | - | - | |
|
| ATCC 12915 | - | - | |
|
| DSM 795 | - | - | |
|
| Nine Mile | - | - | |
|
| DSM 8340 | - | - | |
|
| DSM 30053 | - | - | |
|
| DSM 2570 | - | - | |
|
| ATCC 11303 | - | - | |
|
| ssp. | Isolate from patient | - | - |
|
| ATCC 10211 | - | - | |
|
| ATCC 13883 | - | - | |
|
| NCTC 10332 | - | - | |
|
| DSM 12464 | - | - | |
|
| DSM 9143 | - | - | |
|
| Isolate from patient | - | - | |
|
| Isolate from patient | - | - | |
|
| DSM 1897 | - | - | |
|
| DSM 788 | - | - | |
|
| ATCC10145 | - | - | |
|
| Isolate from patient | - | - | |
|
| DSM 1636 | - | - | |
|
| Isolate from patient | - | - | |
|
| toxin B positive | DSM 19041 | - | - |
|
| DSM 1798 | - | - | |
|
| ATCC 5131 | - | - | |
|
| DSM 20566 | - | - | |
|
| DSM 20565 | - | - | |
|
| ATCC 15748 | - | - | |
|
| Y003 | - | - | |
|
| Y004 | - | - | |
|
| Y005 | - | - | |
|
| Y076 | - | - | |
|
| Y077 | - | - | |
|
| Y078 | - | - | |
|
| Y080 | - | - | |
|
| Y130 | - | - | |
|
| Y225 | - | - | |
|
| Y227 | - | - | |
|
| Y239 | - | - | |
|
| Y241 | - | - | |
|
| Y248 | - | - | |
|
| Y252 | - | - | |
|
| Y259 | - | - | |
|
| Y260 | - | - | |
|
| Y250 | - | - | |
|
| Y428 | - | - | |
|
| Y711 | - | - | |
|
| Y716 | - | - | |
|
| Y718 | - | - | |
|
| Y719 | - | - | |
|
| Y724 | - | - | |
|
| Y728 | - | - | |
|
| Y731 | - | - | |
|
| Y732 | - | - | |
|
| Y734 | - | - | |
|
| Y735 | - | - | |
|
| Y781 | - | - |
Figure 2Amino acid profile of specimen MP 59-I, channel 1 (570 nm) and 2 (440 nm).
The profile represents a typical collagenous pattern with a high amino acid yield. However, aspartic and glutamic acid concentrations are significantly reduced. At 72 min an unidentified peak was detected that did not show up in the other samples.
Figure 3Conventional PCR targeting a 133 bp fragment of gene.
A) Amplification products of the synthetic pla construct at concentrations of 10, 5 and 1 copy, respectively, are shown. Three samples were extracted from ancient bones originating from a modern time cemetery lacking any specific amplicons (bone matrix).
B) Besides the synthetic pla construct, the gel shows products of PCR reactions set up, containing 1 ng DNA of each from the negative panel organisms (Table 2).
C) Gel showing amplification products of aDNA extracted from teeth (Table 1). M: marker, PC: positive control, NTC: no template control, MMC: master mix control, WC: water control, MP: Manching-Pichl, Germany, origin of individuals, E1-8: extraction controls, Ba: Basel, Switzerland, origin of individuals, B: Brandenburg, Germany, origin of individuals.
Comparison of the extraction method by qPCR.
|
|
|
|
|
|
|---|---|---|---|---|
| MP-17 I | 1 | 28 | 460 | - |
| 2 | 34 | 7 | - | |
| 3 | 29 | 210 | - | |
| MP26-I | 1 | neg | - | 32 |
| 2 | neg | - | n.t. | |
| 3 | neg | - | 35 | |
| MP59-I | 1 | 32 | 22 | |
| 2 | neg | - | 34 | |
| 3 | 36 | 2 | - | |
| MPS01-I | 1 | 36 | 2 | - |
| 2 | >40 | ≤ 1 | - | |
| 3 | 37 | 1 | - | |
| B2 | 1 | 37* | ≤ 1 | - |
| 2 | neg* | - | 38 | |
| 3 | neg* | - | 34 |
* 4 µl instead of 2 µl of template aDNA were used
Figure 4qPCR targeting gene screening ancient samples.
Criteria for authenticity.
|
|
|
|---|---|
| Physically isolated pre-PCR-facility with strict decontamination strategy in place using bleach and UV-light, movement only from pre-PCR to post-PCR area | Use of an aDNA laboratory completely isolated and located in a different building than all post-PCR laboratories ( |
| Extraction and PCR controls | Blank controls were performed for each set of extracts or PCR round to a ratio of 1:7 or 1:8 |
| Reproducibility | Multiple PCR rounds from the same or different extractions of each individual yielded consistent results ( |
| Quantification of starting templates | Quantification of the number of starting molecules was carried out by quantitative real time PCR but mainly for methodological reasons and less to prove authenticity |
| Appropriate molecule behaviour | We observed an inverse correlation between amplification efficiency and length of amplicon ( |
| UDG treatment (only [ | UDG treatment was carried out prior to each PCR round |
| Cloning | Direct sequencing of all PCR products was sufficient in this study, cloning was not attempted |
| Independent replication in another aDNA laboratory | In the present study an independent replication was considered not to be necessary; however, the results of a previous study [ |
| Biochemical preservation | The biochemical preservation of bone collagen analysed exemplarily for three individuals indicated that at least the specimens of the largest of the three archaeological sites were preserved well enough to allow DNA analysis |
| Preservation of associated remains | No associated remains e.g. of animals were excavated; instead, human host DNA was amplified, but the significance of the results is limited |